Immutep Ltd Files Routine 6-K Report

Ticker: PRRUF · Form: 6-K · Filed: Jun 24, 2025 · CIK: 1506184

Immutep Ltd 6-K Filing Summary
FieldDetail
CompanyImmutep Ltd (PRRUF)
Form Type6-K
Filed DateJun 24, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 6-K, routine-disclosure

TL;DR

IMMUTEP files routine 6-K, no major news.

AI Summary

Immutep Limited filed a Form 6-K on June 24, 2025, reporting as a foreign private issuer. The company, previously known as Prima BioMed Ltd, is based in Sydney, Australia, and operates in the Pharmaceutical Preparations sector. This filing does not contain specific financial updates or material events but serves as a routine disclosure.

Why It Matters

This filing indicates Immutep is maintaining its reporting obligations as a foreign private issuer with the SEC, which is standard for companies with US listings.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not contain new material information that would immediately impact risk.

Key Players & Entities

  • IMMUTEP Limited (company) — Registrant
  • Prima BioMed Ltd (company) — Former company name
  • June 23, 2025 (date) — Date of report
  • June 24, 2025 (date) — Filing date
  • Sydney, NSW 2000, Australia (location) — Principal executive office address

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K filing is for IMMUTEP Limited, as a foreign private issuer, to report information that it has made or is required to make public pursuant to the laws of Australia, or that it has filed or is required to file with the securities commission of any other jurisdiction, or that it has made or is required to make available to its security holders.

When was IMMUTEP Limited previously known by another name?

IMMUTEP Limited was formerly known as Prima BioMed Ltd, with the date of name change being November 19, 2010.

What is IMMUTEP Limited's standard industrial classification?

IMMUTEP Limited's Standard Industrial Classification is Pharmaceutical Preparations [2834].

Where are IMMUTEP Limited's principal executive offices located?

IMMUTEP Limited's principal executive offices are located at Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia.

Does IMMUTEP Limited file its annual reports under Form 20-F or Form 40-F?

IMMUTEP Limited indicates that it files its annual reports under cover of Form 20-F.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on June 24, 2025 regarding IMMUTEP Ltd (PRRUF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.